Medical Condition News

RSS

New information about biological outcomes and commuting distance

As populations move even further away from urban centers, more people spend longer hours behind the wheel on their way to and from work. While sedentary behavior is known to have adverse effects on cardiovascular and metabolic health, the impact of long commutes by automobile are less understood. A new study has found that greater commuting distances are associated with decreased cardiorespiratory fitness (CRF), increased weight, and other indicators of metabolic risk.

8 May 2012

Stereotaxis to highlight results from Epoch clinical study at HRS annual meeting

Stereotaxis, Inc. will highlight clinical results from the first 1,250 cases and the latest innovations for the Epoch platform, its new generation comprehensive solution for the electrophysiology (EP) laboratory, at the 33rd Annual Heart Rhythm Society (HRS) Scientific Sessions, May 9-12, 2012.

8 May 2012

Campaign announces search for Arizona teens to participate in Addicteen

Arizona's anti-smoking youth campaign, Venomocity Brought to You by Addiction announces a search for Arizona teens to participate in Addicteen, a documentary about addiction. The film will examine activities which teenagers have defined as being addictive including, texting, social media and the use of tobacco. Filmmakers seek to draw out the similarities, differences and impacts of these behaviors on the lives of today's youth.

8 May 2012

CardioFocus’ HeartLight EAS to be highlighted at Heart Rhythm 2012

CardioFocus, Inc., developer of the HeartLight® Endoscopic Ablation System (EAS) for the treatment of atrial fibrillation (AF), announces that its technology will be highlighted both as part of the scientific sessions and during a private academic symposium at Heart Rhythm 2012, the Heart Rhythm Society's 33rd Annual Scientific Sessions, May 9-12 in Boston, MA.

8 May 2012

FRAX version 3.6 now available for 45 countries, in 19 languages

The WHO Fracture Risk Assessment Tool - FRAX- has now been released as version 3.6 with new country models for Chile, Greece, Indonesia, Ireland and Lithuania. Downloadable charts for the newly added countries are also available.

8 May 2012

North Suburban Medical Center's Northeast ER opens today

North Suburban Medical Center's Northeast ER opens its doors today at the corner of Holly Street and 128th Avenue to receive emergency patients from the surrounding communities. The 10,000-foot, state-of- the-art emergency department will function just like a hospital-based ER, treating everything from minor injuries to more severe and life-threatening illnesses such as stroke or heart attack. Northeast ER is a true emergency facility, open 24-hours a day, 365 days a year.

8 May 2012

DBS may offer hope for patients with mild Alzheimer's

A study on a handful of people with suspected mild Alzheimer's disease (AD) suggests that a device that sends continuous electrical impulses to specific "memory" regions of the brain appears to increase neuronal activity. Results of the study using deep brain stimulation, a therapy already used in some patients with Parkinson's disease and depression, may offer hope for at least some with AD, an intractable disease with no cure.

8 May 2012

T2M cells play a crucial role in treatment-resistant asthma

For most people with asthma, a couple of puffs from an inhaler filled with steroids makes breathing easy. But if their lungs become resistant to the calming effect of that medicine, they live in fear of severe asthma attacks that could send them to the hospital - or worse. Now, new research from the University of Michigan Health System may help explain what's going on in the lungs of these steroid-resistant individuals. The findings could aid the development of new treatment options, and of better ways to identify people at risk of becoming steroid-resistant.

8 May 2012

Researchers discover CD19 pathway that leads to lymphoma

Researchers studying the molecular signals that drive a specific type of lymphoma have discovered a key biological pathway leading to this type of cancer. Cancerous cells have been described as being "addicted" to certain oncogenes (cancer-causing genes), and the new research may lay the groundwork for breaking that addiction and effectively treating aggressive types of B cell lymphoma.

8 May 2012

Declining biodiversity may contribute to rise in asthma, allergies

Declining biodiversity may be contributing to the rise of asthma, allergies, and other chronic inflammatory diseases among people living in cities worldwide, a Finnish study suggests. Emerging evidence indicates that commensal microbes inhabiting the skin, airway, and gut protect against inflammatory disorders. However, little is known about the environmental determinants of the microbiome.

8 May 2012

New data from Acucela’s ACU-4429 Phase 2a trial on advanced dry AMD/geographic atrophy

Acucela Inc., a clinical-stage biotechnology company focused on developing new treatments for blinding eye diseases, announced today that the first patient data from the ACU-4429 program were presented during a poster session at The Association for Research in Vision and Ophthalmology (ARVO) 2012 Annual Meeting.

8 May 2012

Zinc oxide could increase risk of skin cancer

As vacationers prepare to spend time outdoors this summer, many of them will pack plenty of sunscreen in hopes it will protect their bodies from overexposure, and possibly from skin cancer. But researchers at Missouri University of Science and Technology are discovering that sunscreen may not be so safe after all.

8 May 2012

Otsuka announces results from aripiprazole Phase 3 trial on schizophrenia

Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S today announced results from a Phase 3 clinical trial evaluating the efficacy, safety and tolerability of once-monthly aripiprazole intramuscular (IM) depot formulation for the maintenance treatment of adults with schizophrenia.

8 May 2012

Specific proteins can help identify patients with IBS

Irritable bowel syndrome (IBS) is hard to diagnose as well as treat, but researchers at the Sahlgrenska Academy, at the University of Gothenburg, Sweden, have discovered a way of confirming the disorder using stool samples.

8 May 2012

Health Canada announces labelling update for Cipralex

Health Canada is informing Canadians of a labelling update for the prescription drug Cipralex (the brand name of the drug escitalopram) regarding a dose-related risk of abnormal heart rhythms. Cipralex is used to treat depression and belongs to a family of drugs known as Selective Serotonin Reuptake Inhibitors (SSRIs).

7 May 2012

New instrument to measure Facebook addiction

Are you a social media enthusiast or simply a Facebook addict? Researchers from Norway have developed a new instrument to measure Facebook addiction, the Bergen Facebook Addiction Scale.

7 May 2012

Intellect Neurosciences announces two new programs in Alzheimer's disease development pipeline

Intellect Neurosciences, Inc., a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer's and other neurological diseases, today announced two new programs in its Alzheimer's disease development pipeline. The new programs are based on two antibodies that target early neurotoxic forms of tau protein, which Intellect intends to develop for therapeutic and diagnostic uses.

7 May 2012

Impairment of daily rhythms has multiple adverse effects on human health

If you're counting calories to lose weight, that may be only part of the weight loss equation says a new research report published online in The FASEB Journal.

7 May 2012

Positive long-term outcome data for chronic ITP patients treated with rituxamab

A new analysis concludes that rituximab, a drug commonly used to treat blood cancers, leads to treatment responses lasting at least five years in approximately one quarter of patients with low platelet counts and a risk of bleeding due to chronic immune thrombocytopenic purpura (ITP).

7 May 2012

Vertex reports interim data from VX-809 and KALYDECO combination Phase 2 study for cystic fibrosis

Vertex Pharmaceuticals Incorporated announced today an interim analysis of data from an ongoing Phase 2 study of VX-809 and KALYDECO (ivacaftor) that showed significant improvements in lung function (FEV1) among adults with cystic fibrosis (CF) who have two copies.

7 May 2012